A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction
NCT ID: NCT03261908
Last Updated: 2018-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2200 participants
OBSERVATIONAL
2018-08-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe
NCT06641661
The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study
NCT00817843
Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function
NCT00189085
A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)
NCT00652301
Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects
NCT05681247
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
wild genotype
Through next generation sequencing, distinguish wild genotype of simvastatin
detection of genotype
detection of genotype by next generation sequencing
mutant genotype
Through next generation sequencing, distinguish mutant genotype of simvastatin
detection of genotype
detection of genotype by next generation sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
detection of genotype
detection of genotype by next generation sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent.
Exclusion Criteria
* Intolerance or unwillingness to blood sample collection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cui Yimin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cui Yimin
Director of pharmacy，M.D & Ph.D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016[1237]
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.